After reading this patent more closely....this "upstream" looks like it could be referring to Phosphatidylserine and now more interesting is the Epiontis collaboration with Peregrine and Turbachova laboratory
--------
The below conference was just in June 2017 and I was surprised to see Epiontis there ....as they discuss secondary endpoints and now imagine those secondary endpoints coming Peregrine's way......also note JUNO presence
It is becoming clear that Precision for Medicine buys out Peregrine partner Epiontis for a very good reason and how is it no matter which way Peregrine closes in on something that looks like it had potential....someone just happens to pass away